Vesugen

What is Vesugen?

Vesugen is a synthetic tripeptide consisting of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp, or KED), developed by Vladimir Khavinson as part of his bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in vascular tissue. Originally derived from animal aorta, Vesugen is positioned as a vascular bioregulator and has been studied in Russian clinical settings for atherosclerosis, lower-limb arterial disease, erectile dysfunction, and age-related decline. About 30 PubMed-indexed papers study the KED sequence (sometimes coded T-38), almost all from Khavinson-affiliated authors, which makes it one of the better-studied Khavinson bioregulators — though much of that work is in neurons, stem cells, and fibroblasts rather than blood vessels.

What Vesugen Is Investigated For

Vesugen is investigated for vascular protection, endothelial dysfunction in aging, atherosclerosis, vasculogenic erectile dysfunction, and broader anti-aging effects within the Khavinson bioregulator framework. It is one of the better-published Russian bioregulators, with about 30 KED-specific PubMed papers. The vascular evidence is in vitro endothelial and vascular-cell work (normalized endothelin-1, restored connexin expression and sirtuin-1, higher Ki-67 and lower E-selectin), plus small Russian clinical reports without control groups: two 41-patient before-and-after studies, one in vasculogenic erectile dysfunction and one after surgery for lower-limb ischemia, each reporting improved blood flow; and a 32-person biological-age study that reported benefits alongside prooxidant activity and a drop in blood-forming stem cells. A 2021 mouse study found KED prevented loss of dendritic spines in an Alzheimer's model. The honest caveats are substantial. Virtually all mechanistic and clinical claims trace to Khavinson-affiliated investigators, Western laboratory replication of the KED-DNA docking interaction is essentially absent, and the Russian clinical reports do not meet modern RCT-methodology standards. The claim that KED (vascular-tropic) and its near-identical sibling KEDA/Livagen (hepatic-tropic) have distinct tissue specificity despite sharing three amino acids lacks independent mechanistic validation. Vesugen's claimed Ki-67 upregulation in vascular tissue is theoretically concerning in oncology contexts and is mechanistically the wrong direction for patients with active malignancy or on anti-angiogenic therapy.

History & Discovery

Vesugen emerged from the bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson and colleagues spent decades fractionating animal-tissue extracts (in this case, calf and porcine aorta) into progressively shorter peptide sequences they claimed retained organ-specific biological activity. Vesugen is the synthetic Cytogen counterpart to the cruder vascular-tissue Cytomax preparation Ventfort, with the active sequence reduced to the tripeptide Lys-Glu-Asp (KED). It shares a backbone with Livagen (KEDA), differing only in a C-terminal alanine — and the Khavinson group's claim that these near-identical sequences nonetheless exhibit distinct tissue tropism (vascular vs. hepatic) is one of the more contentious claims of the entire bioregulator framework. Vesugen sits among the better-published Russian bioregulators, with about 30 KED-specific indexed papers spanning in vitro endothelial models, molecular docking studies of the KED sequence at the MKI67 promoter, and small Russian clinical reports on vasculogenic erectile dysfunction and chronic limb ischemia in elderly patients. Over the 2010s and 2020s the research drifted away from blood vessels: KED has since been studied in aging neurons, a mouse Alzheimer's model, oral and bone-marrow stem cells, and skin and prostate fibroblasts. The footprint is, however, almost entirely concentrated within Khavinson-affiliated laboratories and Russian-language clinical settings; independent Western replication of the in vitro epigenetic mechanism, let alone the clinical effect sizes, is essentially absent.

How It Works

Vesugen is a small three-amino-acid peptide that targets blood vessel cells. It is proposed to enter cell nuclei and turn on genes that keep blood vessels healthy — particularly genes involved in cell renewal and reducing inflammation. As we age, these vascular maintenance genes can become silenced, and Vesugen may help reactivate them.

Vesugen (Lys-Glu-Asp) is proposed to penetrate cell membranes and interact directly with DNA and histone proteins in vascular endothelial cells. The reported molecular effects come from several different cell types. In vascular endothelium in vitro, KED normalized endothelin-1 expression (elevated in atherosclerosis and restenosis), restored connexin expression, and increased sirtuin-1 (PMID 28539025). In vascular cell cultures, the tripeptide coded T-38 (KED) raised the proliferation marker Ki-67 and lowered p53 and E-selectin (PMID 25408528). A computer docking study proposed that KED contacts the MKI67 gene promoter at positions −14 to +12 relative to the transcription start site (PMID 25051766) — a simulation, not a measured interaction. Other effects often attributed to Vesugen were measured outside blood vessels: CXCL12 and a factor reported as WEGC1 in human prostate fibroblasts (PMID 22808515; the Hoxa3 result in that paper came from other peptides); p16 and p21 reductions of 1.82–3.23-fold in oral mesenchymal stem cells (PMID 31677028); nestin and GAP43 in periodontal ligament stem cells (PMID 30791821); FOXO1 inhibition in bone-marrow stem cells (PMID 32399807); and prevention of dendritic-spine loss in a mouse Alzheimer's model at 400 μg/kg (PMID 34071923).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vesugen:

• 01Independent replication outside the Khavinson research program — nearly every mechanistic and clinical claim traces to Khavinson-affiliated investigators. Western laboratory replication of the KED-DNA docking interaction and the in vitro endothelial effects is essentially absent.
• 02Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of a tripeptide), distribution to vascular endothelium, and clearance have not been characterized in humans across routes.
• 03Tissue-specificity mechanism — the claim that KED targets vascular endothelium while the near-identical KEDA targets liver/immune tissue lacks a convincing mechanistic explanation and demands independent validation.
• 04Blinded randomized controlled trials for vascular endpoints — the existing Russian clinical reports on chronic limb ischemia and vasculogenic erectile dysfunction do not meet modern RCT-methodology standards.
• 05Long-term safety in the context of proliferation-marker upregulation — chronic Ki-67 activation in vascular tissue has not been studied for off-target proliferative effects.
• 06The hemopoiesis signal — the only study to look (PMID 26390612) reported reduced CD34+ blood-forming stem cells and prooxidant activity; no follow-up study has checked whether this is real or clinically meaningful.
• 07Comparative efficacy versus first-line vascular pharmacotherapy — no head-to-head studies against statins, antiplatelets, ACE inhibitors, or PDE5 inhibitors exist.

Forms & Administration

Vesugen is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable research-chemical forms, where used, follow the general bioregulator convention of roughly 100–200 mcg per subcutaneous dose (see Dosing); no validated injectable dose exists. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Vesugen is not FDA-approved for any indication. Vascular and erectile-dysfunction claims significantly exceed what the available evidence supports and should not be substituted for evaluation by a clinician familiar with cardiovascular and urologic disease.

Timeline of Effects

Common Questions

Who Vesugen Is NOT For

Drug & Supplement Interactions

There are no documented clinical drug interactions for Vesugen because there are no human pharmacovigilance studies of meaningful scale. What follows is theoretical. The most plausible mechanistic concern is with anti-angiogenic and anti-proliferative oncology agents (bevacizumab, VEGF-pathway tyrosine kinase inhibitors, certain cytotoxic chemotherapies), where Vesugen's claimed activation of vascular endothelial proliferation would be expected to oppose the intended therapeutic effect. A second, more speculative concern is with antihypertensives and nitrate-class vasodilators, given Vesugen's claimed modulation of endothelin-1 and the broader vascular tone signaling environment — but the magnitude in humans is unknown. No CYP-mediated interactions are described, and at the small doses involved, pharmacokinetic interactions at the metabolism level are unlikely. Patients on cardiovascular medication should disclose Vesugen use to their prescribing clinician; absence of documented interaction is not the same as absence of interaction.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions